We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $813M
1-Year Est. Return 101.01%
This Fund
S&P 500
This Quarter Est. Return
+20.53%
1 Year Est. Return
+101.01%
3 Year Est. Return
+357.26%
5 Year Est. Return
+1,392.88%
10 Year Est. Return
–
AUM
$813M
AUM Growth
+$101M
Cap. Flow
+$8.12M
Cap. Flow %
1%
Top 10 Hldgs %
80%
Holding
21
New
4
Increased
9
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$36.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$34.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$32.1M
4
RVMD icon
Revolution Medicines
RVMD
+$22.2M
5
LLY icon
Eli Lilly
LLY
+$15.1M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$65.1M
2
ISRG icon
Intuitive Surgical
ISRG
+$46M
3
NUVL
Nuvalent
NUVL
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$17.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$671B
$108M 13.27%
424,945
+10,442
+3% +$2.43M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$141B
$100M 12.33%
201,791
+72,477
+56% +$32.1M
LLY icon
3
Eli Lilly
LLY
$1.03T
$91.8M 11.29%
76,532
+14,737
+24% +$15.1M
ASND icon
4
Ascendis Pharma A/S
ASND
$17.8B
$69M 8.49%
258,740
+3,408
+1% +$796K
DXCM icon
5
DexCom
DXCM
$33.9B
$55.3M 6.8%
820,479
+122,321
+18% +$8.15M
AXSM icon
6
Axsome Therapeutics
AXSM
$10.9B
$53.7M 6.6%
219,308
+157,192
+253% +$34.1M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$16.1B
$53.4M 6.57%
221,720
+63,057
+40% +$13.8M
ELVN icon
8
Enliven Therapeutics
ELVN
$4.37B
$44M 5.41%
+866,716
New +$36.8M
ARGX icon
9
argenx
ARGX
$65.9B
$38.6M 4.75%
41,596
+9,961
+31% +$8.22M
MDGL icon
10
Madrigal Pharmaceuticals
MDGL
$12.5B
$36.7M 4.51%
68,273
-35,015
-34% -$17.9M
RVMD icon
11
Revolution Medicines
RVMD
$45.2B
$28.4M 3.5%
+151,822
New +$22.2M
UTHR icon
12
United Therapeutics
UTHR
$21B
$25.5M 3.13%
47,026
-23,344
-33% -$13.1M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$42.7B
$25.3M 3.11%
746,835
-274,173
-27% -$9.13M
TARS icon
14
Tarsus Pharmaceuticals
TARS
$3.65B
$20.7M 2.54%
328,340
+75,752
+30% +$4.84M
ISRG icon
15
Intuitive Surgical
ISRG
$131B
$19.1M 2.35%
47,983
-105,267
-69% -$46M
CYTK icon
16
Cytokinetics
CYTK
$10.3B
$16.5M 2.03%
+194,000
New +$13.9M
DNTH icon
17
Dianthus Therapeutics
DNTH
$6.03B
$11.8M 1.45%
120,712
-24,831
-17% -$2.17M
BBNX
18
Beta Bionics
BBNX
$896M
$7.73M 0.95%
+493,344
New +$5.87M
DFTX
19
Definium Therapeutics
DFTX
$5.11B
$7.67M 0.94%
162,996
-206,592
-56% -$5.11M
NUVL
20
DELISTED
Nuvalent
NUVL
– –
-308,506
Closed -$31.6M
TMO icon
21
Thermo Fisher Scientific
TMO
$229B
– –
-132,413
Closed -$65.1M

Similar funds

BPIM
Brant Point Investment Management New York $813M AUM 60.46% 1-Year Est. Return
REA
Renesas Electronics America San Jose, California $813M AUM
CFO
Cambient Family Office Ada, Michigan $813M AUM
FA
Fagan Associates Troy, New York $813M AUM 37.92% 1-Year Est. Return
WAM
Wallington Asset Management Indianapolis, Indiana $814M AUM 50.75% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
TVPW
Third View Private Wealth Westport, Connecticut $814M AUM
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Tri Locum Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Tri Locum Partners held 21 positions worth $813M, up 14% from $713M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Tri Locum Partners's Q2 2026 filing shows 4 new, 9 increased, 6 reduced and 2 closed positions. Its largest new stake was Enliven Therapeutics: 866,716 shares worth $44M. The largest sale was Thermo Fisher Scientific, an estimated $65.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Tri Locum Partners's largest Q2 2026 buy was Enliven Therapeutics: 866,716 shares worth $44M.
  • Tri Locum Partners added most to Axsome Therapeutics in Q2 2026, an estimated $34.1M increase.
  • Tri Locum Partners's biggest Q2 2026 reduction was Intuitive Surgical, cutting an estimated $46M.
  • Tri Locum Partners fully exited Thermo Fisher Scientific in Q2 2026, selling an estimated $65.1M.
  • Tri Locum Partners's ten largest holdings make up 80% of its $813M portfolio in Q2 2026.
  • Tri Locum Partners opened 4 new positions and closed 2 in Q2 2026.
  • Tri Locum Partners's portfolio value rose 14% quarter-over-quarter to $813M.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.